Contract 75A50124C00003

Mapp Biopharmaceutical, Inc. · Department Of Health And Human Services · August 13, 2024

Cost Plus Fixed FeeFull & Open CompetitionNAICS 541714

Mapp Biopharmaceutical, Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on August 13, 2024 for $3.00 million (current value) of work in research and development in biotechnology (except nanobiotechnology). Performance is in San Diego, CA. It was awarded under full and open competition. The contract has been modified 1 time since the base award It uses cost-plus contract pricing. The most recent modification was on June 24, 2025. If all options are exercised, the contract could reach $38.24 million.

Current value
$3.00M
Potential value
$38.24M
if all options exercised
Modifications
1
Latest June 24, 2025

Contract details

PIID
75A50124C00003
Award type
Definitive Contract
Pricing
Cost Plus Fixed Fee
Set-aside
No Set Aside Used.
Competition
Full And Open Competition
NAICS
541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
Product / service
General Science And Technology R&D Services; General Science And Technology; Basic Research
Place of performance
San Diego, CA
First action
August 13, 2024
Latest action
June 24, 2025

Description

THE PURPOSE OF THE UNILATERAL NO COST MODIFICATION IS TO DESIGNATE THE ALTERNATE COR DR. SAIMA ZAMAN AS THE PRIMARY COR IAW THE EXECUTED COR DESIGNATION MEMORANDUM. DR. CAROL DIAZ-DIAZ WILL ASSUME THE POSITION OF ALTERNATE COR.

Modification timeline

  • June 24, 2025
    Mod P00010 · Other Administrative Action
    $3.00M
  • August 13, 2024
    Mod P00001 · Other Administrative Action
    NO COST MODIFICATION TO REVISE INDIRECT RATES IN SECTION G.7.
    $2.96M

Similar contracts

RecipientAgencyDateObligated
Vericel CorporationDepartment Of Health And Human ServicesApril 1, 2026$34.88M
Ceramedix Holding, LlcDepartment Of Health And Human ServicesMarch 31, 2026$4.22M
American College Of Medical Toxicology, Inc.Department Of Health And Human ServicesMarch 31, 2026$0
Glaxosmithkline, LlcDepartment Of Health And Human ServicesMarch 31, 2026$7.79M
Care Access Research LlcDepartment Of Health And Human ServicesMarch 31, 2026$2.55M
Pattern Bioscience, Inc.Department Of Health And Human ServicesMarch 31, 2026$22.50M

Top contractors in NAICS 541714

Lifetime obligated dollars across all federal contracts in this NAICS code.

#ContractorContractsObligated
1Amgen USA Inc1$59.99M
2Vericel Corporation1$34.88M
3Spectral Md, Inc.1$31.67M
4Ppd Development Lp6$31.12M
5L3 Technologies, Inc.1$22.00M
6Technical Resources International, Inc.6$21.80M
7Abbott Laboratories1$21.01M
8Paratek Pharmaceuticals, Inc1$17.47M
9Ossium Health, Inc.1$12.39M
10Rho Federal Systems Division Inc1$8.00M

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

✓ You’re on the list. We’ll never spam you.

Helpful guides

Continue learning

See all guides →
More on BesaGov

Keep researching

Track this contract, set alerts on similar opportunities, and build proposal pipelines on BesaGov.
Sign up free

Frequently asked questions

What is contract 75A50124C00003?

Contract 75A50124C00003 is a federal contract awarded to Mapp Biopharmaceutical, Inc. by Department Of Health And Human Services on August 13, 2024 for $3.00 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 1 time since the base award.

Who won contract 75A50124C00003?

Mapp Biopharmaceutical, Inc. won contract 75A50124C00003 from Department Of Health And Human Services.

How much is contract 75A50124C00003 worth?

Contract 75A50124C00003 has obligated $0 to date but carries a potential ceiling of $38.24 million if fully funded and all options are exercised.